BIOMAT Database Logo BIOMAT Database Logo

Impact and Cost-Effectiveness of Oncotype DX for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer. 2021

Fadi El Karak, and Elie Rassy, and Josiane Bassil, and Mohamed Awali, and Colette Hanna, and Anthony Saroufim, and Fadi Nasr, and Fadi Farhat, and Joseph Kattan, and Marwan Ghosn, and Mike Paulden
Department of Medical Oncology, Saint Joseph University, Faculty of Medicine, Beirut, Lebanon.

BACKGROUND Oncotype DX is approved in multiple countries but its cost-effectiveness is a matter of considerable health debate. Lebanon is high-middle income country according to the World Bank classification however it is facing a mounting financial and health care burden from cancer. Therefore, we conducted a costeffectiveness analysis of Oncotype DX based Lebanese on real-life data. METHODS We updated a Canadian cost-effectiveness model of Oncotype DX by incorporating Lebanese data. The patient population was a real-life cohort of 82 women diagnosed with hormone receptor - positive and HER2 - negative early breast cancer. RESULTS Overall, providing Oncotype DX to only intermediate Adjuvant! Online risk patients costs an additional $83 CAD (93,883 LBP) per additional QALY. From this point, extending provision to also cover high Adjuvant! Online risk patients costs an additional $736 CAD (831,578 LBP) per additional QALY. From this point, extending provision further to also cover low Adjuvant! Online risk patients (such that Oncotype DX is provided to all patients) costs an additional $14,562 CAD (16.46m LBP) per additional QALY. Given that most women in our population-based sample were classified as intermediate Adjuvant! Online risk patients, our study focused on this subset in the second analysis. Providing Oncotype DX to intermediate Adjuvant! Online risk patients has a relatively small additional cost compared to not providing Oncotype DX, and results in a relatively large QALY gain. The incremental cost per QALY is $2,022 CAD (2.29m LBP), implying that Oncotype DX is cost-effective for intermediate Adjuvant! Online risk patients if the willingness-to-pay for a QALY is greater than 2.29m LBP. CONCLUSIONS As one of the few economic evaluations to date conducted using Lebanese data, this evaluation provides information to decision makers regarding the cost-effectiveness of providing Oncotype DX to Lebanese patients.

UI MeSH Term Description Entries
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017024 Chemotherapy, Adjuvant Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. Adjuvant Chemotherapy,Drug Therapy, Adjuvant,Adjuvant Drug Therapy

Related Publications

Fadi El Karak, and Elie Rassy, and Josiane Bassil, and Mohamed Awali, and Colette Hanna, and Anthony Saroufim, and Fadi Nasr, and Fadi Farhat, and Joseph Kattan, and Marwan Ghosn, and Mike Paulden
The effect of Oncotype DX® on adjuvant chemotherapy treatment decisions in early breast cancer.
November 2019, Annals of the Royal College of Surgeons of England,
Fadi El Karak, and Elie Rassy, and Josiane Bassil, and Mohamed Awali, and Colette Hanna, and Anthony Saroufim, and Fadi Nasr, and Fadi Farhat, and Joseph Kattan, and Marwan Ghosn, and Mike Paulden
Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
January 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research,
Fadi El Karak, and Elie Rassy, and Josiane Bassil, and Mohamed Awali, and Colette Hanna, and Anthony Saroufim, and Fadi Nasr, and Fadi Farhat, and Joseph Kattan, and Marwan Ghosn, and Mike Paulden
Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer.
April 2019, Urology,
Fadi El Karak, and Elie Rassy, and Josiane Bassil, and Mohamed Awali, and Colette Hanna, and Anthony Saroufim, and Fadi Nasr, and Fadi Farhat, and Joseph Kattan, and Marwan Ghosn, and Mike Paulden
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer.
June 2023, NPJ breast cancer,
Fadi El Karak, and Elie Rassy, and Josiane Bassil, and Mohamed Awali, and Colette Hanna, and Anthony Saroufim, and Fadi Nasr, and Fadi Farhat, and Joseph Kattan, and Marwan Ghosn, and Mike Paulden
Cost analysis of using Magee scores as a surrogate of Oncotype DX for adjuvant treatment decisions in women with early breast cancer.
June 2020, Journal of evaluation in clinical practice,
Fadi El Karak, and Elie Rassy, and Josiane Bassil, and Mohamed Awali, and Colette Hanna, and Anthony Saroufim, and Fadi Nasr, and Fadi Farhat, and Joseph Kattan, and Marwan Ghosn, and Mike Paulden
Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.
January 2022, Journal of medical economics,
Fadi El Karak, and Elie Rassy, and Josiane Bassil, and Mohamed Awali, and Colette Hanna, and Anthony Saroufim, and Fadi Nasr, and Fadi Farhat, and Joseph Kattan, and Marwan Ghosn, and Mike Paulden
The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.
August 2013, The Medical journal of Australia,
Fadi El Karak, and Elie Rassy, and Josiane Bassil, and Mohamed Awali, and Colette Hanna, and Anthony Saroufim, and Fadi Nasr, and Fadi Farhat, and Joseph Kattan, and Marwan Ghosn, and Mike Paulden
Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer.
January 2022, ClinicoEconomics and outcomes research : CEOR,
Fadi El Karak, and Elie Rassy, and Josiane Bassil, and Mohamed Awali, and Colette Hanna, and Anthony Saroufim, and Fadi Nasr, and Fadi Farhat, and Joseph Kattan, and Marwan Ghosn, and Mike Paulden
Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria.
December 2020, Breast care (Basel, Switzerland),
Fadi El Karak, and Elie Rassy, and Josiane Bassil, and Mohamed Awali, and Colette Hanna, and Anthony Saroufim, and Fadi Nasr, and Fadi Farhat, and Joseph Kattan, and Marwan Ghosn, and Mike Paulden
Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
May 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
Copied contents to your clipboard!